Volume 25, Issue 7 e14086
ORIGINAL ARTICLE

A shifting landscape: Practice patterns and outcomes of cystic fibrosis and non-cystic fibrosis pediatric lung transplantation

Jennifer S. Nelson

Corresponding Author

Jennifer S. Nelson

Department of Cardiovascular Services, Nemours Children’s Hospital, Orlando, FL, USA

University of Central Florida College of Medicine, Orlando, FL, USA

Correspondence

Jennifer S. Nelson, Department of Cardiovascular Services, Nemours Children’s Hospital, 6535 Nemours Parkway, Orlando, FL 32827, USA

Email: [email protected]

Search for more papers by this author
Timothy M. Maul

Timothy M. Maul

Department of Cardiovascular Services, Nemours Children’s Hospital, Orlando, FL, USA

Search for more papers by this author
Shelby L. Aughtman

Shelby L. Aughtman

University of Central Florida College of Medicine, Orlando, FL, USA

Search for more papers by this author
Christopher G. Hurtado

Christopher G. Hurtado

University of Central Florida College of Medicine, Orlando, FL, USA

Search for more papers by this author
Peter D. Wearden

Peter D. Wearden

Department of Cardiovascular Services, Nemours Children’s Hospital, Orlando, FL, USA

Search for more papers by this author
First published: 18 July 2021
Citations: 1

Abstract

Background

New drugs may further decrease the need for lung transplant (LTx) in pediatric patients with cystic fibrosis (CF), but few studies highlight pediatric non-CF LTx characteristics and outcomes.

Methods

The ISHLT registry was used to report morbidity, graft failure, and survival for primary pediatric (<18 years) LTx performed 1990–2017. Recipient/donor characteristics and long-term outcomes were analyzed for CF and non-CF recipients. Survival was assessed using Kaplan–Meier curves.

Results

Of 2232 primary LTx, (43% in males), 918 (41%) were performed for non-CF indications; most commonly pulmonary hypertension (43%). Non-CF patients were younger (median age 11 vs. 15, < .001), and more frequently on inotropes and/or extracorporeal membrane oxygenation (15% vs. 2.4%, < .001) at transplant, compared to CF recipients. In-hospital major complications more commonly affected CF LTx recipients (57% vs. 48%, = .003), but 30-day mortality was higher in the non-CF group (9% non-CF vs. 5% CF, < .001). One-, five-, and ten-year mortality was 18%, 50%, and 65% for CF recipients, respectively, and 21%, 45%, and 58% for non-CF recipients (= .01 at 10 years). Five-year survival was significantly better for non-CF females versus CF females (56% vs. 48%, = .013), but was similar between groups for males (55% vs. 54%, = .305). While age was a late outcomes risk factor, pulmonary hypertension and later transplants eras were protective.

Conclusions

Early mortality is higher and late mortality is lower in non-CF LTx. Current non-CF LTx outcomes leave room for improvement. Further study is needed to evaluate the effects of center volume and pediatric-specific experience on outcomes.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from The International Society for Heart and Lung Transplantation International Thoracic Organ Transplant Registry (ISHLT). Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the authors with the permission of the ISHLT.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.